These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29741439)

  • 1. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
    Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
    J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A; Greene M; Hartry A; Burudpakdee C
    J Med Econ; 2018 Sep; 21(9):888-901. PubMed ID: 29862860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic burden of sarcoidosis in a commercially-insured population in the United States.
    Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
    J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
    Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
    Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity.
    Murage MJ; Anderson A; Oliveria SA; Casso D; Ojeh CK; Muram TM; Merola JF; Araujo AB
    J Med Econ; 2018 Aug; 21(8):745-754. PubMed ID: 29718756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
    Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
    J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare costs in psoriasis and psoriasis sub-groups over time following psoriasis diagnosis.
    Al Sawah S; Foster SA; Goldblum OM; Malatestinic WN; Zhu B; Shi N; Song X; Feldman SR
    J Med Econ; 2017 Sep; 20(9):982-990. PubMed ID: 28635342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.
    Bradford Rice J; White A; Lopez A; Galebach P; Schepman P; Popelar B; Philbin M
    J Med Econ; 2016 Jul; 19(7):649-54. PubMed ID: 26850074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
    Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
    J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between adherence to levothyroxine and economic and clinical outcomes in patients with hypothyroidism in the US.
    Hepp Z; Lage MJ; Espaillat R; Gossain VV
    J Med Econ; 2018 Sep; 21(9):912-919. PubMed ID: 29865926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopag.
    Cai B; Said Q; Li X; Li FY; Arcona S
    J Med Econ; 2020 Mar; 23(3):243-251. PubMed ID: 31686551
    [No Abstract]   [Full Text] [Related]  

  • 12. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic burden and risk factors of migraine disease progression in the US: a retrospective analysis of a commercial payer database.
    Foster SA; Chen CC; Ding Y; Mason O; McGuiness CB; Morrow P; Ye W; Wade RL; Smith TR; Joshi S
    J Med Econ; 2020 Nov; 23(11):1356-1364. PubMed ID: 32845189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population.
    Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
    Curr Med Res Opin; 2018 Aug; 34(8):1519-1527. PubMed ID: 29741130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis.
    Charlton M; Tonnu-Mihara I; Teng CC; Zhou Z; Asefaha F; Luthra R; Hoovler A; Uzoigwe C
    J Med Econ; 2024; 27(1):919-930. PubMed ID: 38953706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burden of venous leg ulcers in the United States.
    Rice JB; Desai U; Cummings AK; Birnbaum HG; Skornicki M; Parsons N
    J Med Econ; 2014 May; 17(5):347-56. PubMed ID: 24625244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.
    Khemiri A; Kharitonova E; Zah V; Ruby J; Toumi M
    Postgrad Med; 2014 Sep; 126(5):113-20. PubMed ID: 25295655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.